Authors:
Monali Tayade, Shishanka Wangnoo
Download free PDF
Artificial Intelligence in Medical Imaging Market Size & Share 2026-2035
Report ID: GMI5378
|
Published Date: August 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Artificial Intelligence in Medical Imaging Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
AI in Medical Imaging Market Size
The global AI in medical imaging market was valued at USD 2.1 billion in 2025 and is projected to reach USD 19.6 billion by 2035, expanding at a 23.9% CAGR from 2026 to 2035. The market reaches an estimated USD 2.8 billion in 2026.
Artificial Intelligence in Medical Imaging Market Key Takeaways
Market Leader: GE Healthcare led with over 23% market share in 2025.
Leading Players: Top 5 players in this market include GE HealthCare, Siemens Healthineers, Philips Healthcare, Aidoc, Viz.ai, which collectively held a market share of 65% in 2025.
AI-enabled imaging now sits within clinical diagnostic infrastructure rather than a stand-alone software niche, as health systems combine image interpretation, case prioritization, reporting, and care coordination within connected workflows. The U.S. Food and Drug Administration had authorized more than 1,500 AI-enabled medical devices by mid-2026, with radiology representing approximately 76% of authorizations. [1]U.S. Food and Drug Administration, "Artificial Intelligence and Machine Learning in Software as a Medical Device," fda.gov
The market covers software and platform revenues generated by AI tools used to analyze medical images, prioritize imaging worklists, support diagnosis, improve acquisition or reconstruction quality, automate reporting, and guide treatment planning. It includes cloud-based and on-premises deployments across X-ray, computed tomography, magnetic resonance imaging, ultrasound, molecular imaging, nuclear imaging, and other image-based modalities. Imaging hardware revenue that lacks an AI software or algorithmic component falls outside the market boundary.
Market estimates combine bottom-up assessment of vendor platform activity and clinical deployment use cases with top-down validation against regulatory authorization trends, imaging infrastructure availability, and diagnostic workflow demand. OECD evidence indicates that CT and MRI examination availability and use continue to expand across member countries, strengthening the procedure base that supports AI imaging software economics. [2]Organisation for Economic Co-operation and Development, "Health at a Glance 2025," oecd.org
GMI Analyst View
The market will move from algorithm procurement toward enterprise workflow procurement through 2030. The immediate catalyst is not image recognition alone; hospital buyers increasingly need a controlled way to manage numerous algorithms across PACS, radiology information systems, and clinical communication channels. Cloud-hosted orchestration will gain share where health systems can standardize governance and data controls across multiple sites. On-premises and hybrid architectures will remain necessary in jurisdictions and clinical settings where latency, localization, or data sovereignty outweigh cloud deployment advantages. The second-order effect is a higher competitive premium on integration depth, because vendors that reduce implementation friction can convert clinical validation into recurring enterprise revenue more consistently than single-purpose tools.
Key Drivers
Technological Advancements in AI
Deep learning, transformer architectures, and computer vision are broadening AI use across image analysis, reconstruction, workflow automation, and clinical decision support. Controlled studies have reported liver segmentation Dice scores above 95%, while meta-analyses place AI lung nodule detection performance across chest radiographs and CT at AUC values from 0.864 to 0.937. [3]PMC National Library of Medicine, "Deep Learning Approaches in Medical Image Analysis," pmc.ncbi.nlm.nih.gov The FDA authorized 295 AI/ML-enabled medical devices during 2025, with radiology accounting for 75% of clearances. This clearance volume widens the commercial product pool available to community hospitals and outpatient imaging centers.
Shortage of Radiologists Accelerating AI Adoption
Imaging utilization is projected to rise 16.9% to 26.9% by 2055, while radiologist supply is projected to increase 25.7% under current residency conditions. [4]Harvey L. Neiman Health Policy Institute, "Radiologist Workforce and Imaging Utilization Projections," neimanhpi.org The supply-demand imbalance changes the commercial case for AI from marginal productivity improvement to workflow capacity support. Triage systems can elevate suspected hemorrhage, large vessel occlusion, pulmonary embolism, and aortic dissection cases before a radiologist begins routine reading. Automated reporting tools also reduce time spent on repetitive documentation, though final clinical accountability remains with the interpreting clinician.
Improved Diagnostic Accuracy and Treatment Planning
Deep learning systems have achieved AUC values of 0.868 to 0.909 for breast cancer detection across mammography, ultrasound, MRI, and digital breast tomosynthesis. [5]PubMed National Library of Medicine, "Deep Learning for Breast Cancer Detection: Systematic Review and Meta-Analysis," pubmed.ncbi.nlm.nih.gov Diagnostic confidence is most valuable where early detection or measurement consistency changes downstream treatment selection. AI also supports radiation therapy planning through organ-at-risk segmentation, tumor contouring, and dose optimization. As evidence expands, procurement decisions will increasingly focus on real-world performance across local patient populations rather than controlled benchmark scores alone.
Rising R&D Investment Supporting Innovation and Market Expansion
Research funding and private investment are advancing low-dose MRI reconstruction, AI-assisted cardiac imaging, and multimodal clinical data integration. The National Institute of Biomedical Imaging and Bioengineering supports research programs across these technical areas. [6]National Institutes of Health, "National Institute of Biomedical Imaging and Bioengineering Research Programs," nih.gov Investment is concentrating around oncology and cardiovascular applications, where clinical pathways and reimbursement potential are more mature. Over time, larger training datasets and foundation-model architectures may shift differentiation from isolated algorithm performance toward model adaptability, governance, and deployment scale.
Key Restraints
Slow Regulatory Approval Process
European developers must navigate Medical Devices Regulation (EU MDR 2017/745) alongside the EU AI Act, Regulation (EU) 2024/1689. Guidance issued in June 2025 addressed the interaction between these frameworks for AI-enabled medical devices. [7]European Commission Health and Food Safety, "MDCG 2025-6 Guidance on Medical Devices Regulation and the AI Act," health.ec.europa.eu In the United States, median AI/ML medical-device clearance time reached 142 days in 2025. These timelines can delay commercialization, increase regulatory staffing needs, and constrain smaller vendors with narrower funding runways.
Risk of Patient Safety Concerns Due to AI-Driven Diagnostic Errors
Models trained on curated academic datasets may underperform in community settings where acquisition protocols, disease prevalence, and patient demographics differ from development populations. [4]Harvey L. Neiman Health Policy Institute, "Radiologist Workforce and Imaging Utilization Projections," neimanhpi.org The constraint is especially material in oncology and neurology, where false negatives, false positives, or incorrect prioritization can affect clinical decisions. Real-world monitoring, local validation, clinician oversight, and post-market surveillance therefore remain central to adoption. Vendors that demonstrate performance stability across sites will have a stronger position in enterprise procurement.
GMI Analyst View
Regulatory and safety requirements will not halt adoption; they will raise the commercial threshold for participation. Large imaging vendors and AI-native platforms with clinical evidence, quality systems, and enterprise integration resources will have an advantage as regulators require more rigorous lifecycle controls. By 2028, health systems will increasingly favor vendors that can document local performance monitoring and workflow accountability. Primary research conducted across 280 radiology department heads in 12 countries during Q2 2025 indicated that enterprise platform integration capability had become the leading vendor-selection criterion, ahead of individual algorithm performance benchmarks. The implication is clear: governance, deployment, and interoperability will become as commercially important as detection accuracy.
AI in Medical Imaging Market Segment Analysis
By Deployment
Cloud-based solutions held 57.6% of market revenue in 2025. Cloud deployment supports rapid updates, scalable computing for large imaging datasets, and lower upfront capital requirements for hospitals and diagnostic networks. GE HealthCare's Edison platform and Aidoc's cloud-native operating system illustrate how vendors can distribute multi-algorithm workflows across hospital networks. Cloud connectivity also supports standardized software releases and centralized performance monitoring.
On-premises systems held 42.4% share in 2025. Academic medical centers, government hospitals, and institutions operating under strict data-localization rules continue to require local deployment. Siemens Healthineers and Philips Healthcare retain an advantage in this segment through established imaging hardware relationships. Hybrid designs will become more common through 2030 because they keep latency-sensitive inference local while shifting updates, training, and noncritical analytics to cloud environments.
By Modality
X-ray held the largest modality share at 27.1% in 2025. Its installed base, high examination volume, and extensive datasets support applications in chest imaging, fracture detection, dental imaging, and tuberculosis screening. Lunit INSIGHT CXR, Aidoc tools, Annalise.ai Enterprise CXR, and Subtle Medical platforms reflect the breadth of commercial activity in image-based AI. Chest X-ray tools have reported AUC values approaching 0.93 in peer-reviewed evidence.
Computed tomography held 24.5% share. CT applications include lung nodule detection, liver segmentation, coronary calcium scoring, stroke triage, and vascular analysis. Canon Medical Systems and Siemens Healthineers are embedding AI reconstruction and analysis into CT acquisition environments. CT's large image volumes and complex interpretation burden make it a central segment for enterprise AI deployment.
MRI accounted for 17.6% share. MRI AI supports lesion segmentation, accelerated reconstruction, prostate assessment, cardiac quantification, and motion correction. SubtleMR improves image quality and can reduce acquisition time across 1.5T and 3T systems. Research initiatives supported by the National Institute of Biomedical Imaging and Bioengineering include low-dose and contrast-enhanced MRI reconstruction using deep learning.
Ultrasound held 12.3% share. AI-guided acquisition, fetal biometry, echocardiography analysis, thyroid classification, and point-of-care support create demand beyond conventional radiology departments. Butterfly Network's iQ+ combines handheld ultrasound with AI-assisted optimization and interpretation support. This segment will benefit from clinic and telehealth deployment models through 2035.
Molecular imaging accounted for 8.7% share, while nuclear imaging represented 6.5%. PET, SPECT, PET/CT, and PET/MRI applications focus on tracer quantification, lesion detection, therapy response, and theranostic dosimetry. OECD data indicates increasing PET scanner availability across member countries. GE HealthCare's nuclear medicine AI tools integrated with SPECT/CT systems show how specialized modalities can support high-value, lower-volume AI use cases.
Other modalities represented 3.3% share and include optical coherence tomography, digital pathology, dermatoscopy, capsule endoscopy, and retinal imaging. AI systems in retinal OCT analysis have reported AUC values from 0.933 to 1.00 across selected conditions. Commercial deployment remains earlier than in X-ray or CT, but these modalities extend AI-enabled diagnostics into primary care and specialty settings.
By Indication
Lung imaging led with 22.8% share in 2025. Low-dose CT screening, chest radiography, tuberculosis detection, COPD assessment, and lung nodule management generate substantial demand for AI support. Aidoc's lung suite and Lunit INSIGHT CXR are prominent commercial platforms. Expanded lung screening eligibility in the United States and United Kingdom will increase interpretation volume and reinforce demand for triage and detection tools.
Breast imaging accounted for 18.1% share. Mammography, digital breast tomosynthesis, ultrasound, and MRI applications are supported by mature clinical validation. Hologic's Genius AI Detection 2.0 received FDA 510(k) clearance in 2025. AI will increasingly serve as a co-reader and quality-control layer in screening programs rather than a replacement for specialist review.
Cardiovascular applications represented 17.6% share and are positioned as the fastest-growing indication. Cleerly's coronary CT angiography platform quantifies plaque and stenosis from CT data, while AI-assisted echocardiography automates ejection fraction and wall-motion analysis. Reimbursement maturity and higher use of coronary CT angiography will support commercial adoption through 2035.
Orthopedics held 15.4% share. Emergency fracture detection, bone-age assessment, vertebral fracture grading, implant assessment, and osteoporosis screening create a large-volume use case. RapidAI's expansion into musculoskeletal applications reflects movement beyond acute stroke and vascular imaging. Routine CT-derived bone-density assessment may become an important secondary use case because it extracts actionable data from studies acquired for other reasons.
Neurology accounted for 10.2% share. RapidAI RAPID and Viz.ai large vessel occlusion detection tools support stroke triage, while MRI-based applications quantify white matter lesions and neurodegenerative biomarkers. AI's value comes from compressing time to intervention in acute stroke and improving consistency in longitudinal assessment.
Liver imaging accounted for 8.8% share. AI supports hepatocellular carcinoma detection, liver segmentation, fatty liver quantification, cirrhosis staging, and surgical planning. Philips Healthcare's AI-assisted liver MRI tools and deep learning liver segmentation systems demonstrate the connection between imaging analysis and pre-operative planning.
Other indications represented 7.1% share. Prostate MRI, thyroid ultrasound, renal imaging, gastrointestinal imaging, and ophthalmology broaden clinical utility beyond large radiology indications. The strategic value lies in platform expansion: one deployed workflow layer can support multiple specialties once algorithms, governance, and reporting integrations are established.
By Application
Diagnostic decision support led applications with 42.6% share in 2025. These tools flag suspected findings, generate probability outputs, and support structured diagnostic reporting. The FDA's AI authorization portfolio remains concentrated in computer-aided detection and diagnosis systems that assist clinicians rather than replace them. DICOM-native integration with PACS is becoming a core requirement because hospitals need AI outputs within established reading workflows.
Radiation therapy planning accounted for 16.9% share. AI-based auto-segmentation, tumor contouring, adaptive planning, and dose optimization reduce manual planning time. Philips Healthcare, Varian, and RaySearch Laboratories have developed commercially relevant planning workflows. MRI-guided linear accelerators will increase demand for real-time adaptive AI planning through the forecast period.
Longitudinal disease monitoring represented 14.2% share. Automated tumor measurement, lesion-volume tracking, RECIST and iRECIST assessment, and neurodegenerative monitoring improve consistency across repeated studies. Tempus Radiology links longitudinal imaging data with genomic and molecular context, expanding the application from measurement automation into precision oncology decision support.
Surgical and interventional planning accounted for 11.1% share. AI-generated 3D anatomy models support aortic sizing, structural heart interventions, hepatic surgery, and image-guided procedures. Integration with robotic procedure preparation creates an additional route to adoption. The commercial value is tied to procedure planning, reduced variation, and more standardized pre-operative assessment.
Clinical research and trials represented 8.9% share. Automated endpoint measurement, retrospective archive analysis, and imaging biomarker extraction reduce manual annotation workloads in trials. Annalise.ai and specialized imaging trial vendors are building platforms for the data and regulatory requirements of oncology studies. Regulatory clarity around AI-generated imaging endpoints will determine the pace of expansion.
Other applications represented 6.3% share. Rad AI's Impressions platform illustrates reporting workflow automation, while scanner-level protocol optimization can reduce radiation dose and improve acquisition efficiency. Training simulation, quality assurance, scheduling, and resource utilization remain earlier-stage use cases.
By End Use
Hospitals held 56.1% share in 2025. Academic medical centers and integrated delivery networks have the imaging volume, governance infrastructure, and IT budgets required for enterprise deployments. GE HealthCare, Siemens Healthineers, and Philips Healthcare target these accounts through platform and long-term service relationships. Government hospitals in India, Southeast Asia, and Latin America will become a more material source of incremental demand as national digitization efforts expand.
Diagnostic centers accounted for 21.8% share. Freestanding imaging facilities, teleradiology providers, and imaging chains are economically motivated to use triage and reporting AI because throughput directly affects operating margins. Aidoc and Viz.ai offer cloud-enabled workflows suited to centers that process high study volumes without on-site radiologists at all times. Consolidation among diagnostic networks will create larger accounts capable of enterprise-scale procurement.
Clinics held 18.1% share. Cardiology, orthopedic, oncology, and multispecialty clinics use modality-specific AI tools for ultrasound, digital X-ray, echocardiography, and musculoskeletal imaging. Subscription and per-study pricing models reduce barriers for smaller facilities. Portable imaging and point-of-care AI will be the principal clinic growth pathway through 2035.
Other end users represented 4.0% share. Research institutions, government agencies, military health systems, veterinary imaging centers, and public-health programs create specialized demand. Tuberculosis screening, cancer detection, maternal imaging, and remote triage programs demonstrate how AI can support capacity where specialist access is limited.
GMI Analyst View
Segment growth will be determined less by a single modality than by the ability to connect high-volume image acquisition with clinically actionable workflow outputs. X-ray and CT will remain the broadest deployment categories because their volume and regulatory maturity support scale. MRI, cardiovascular imaging, and longitudinal monitoring will create higher-value growth opportunities because AI can address time-intensive interpretation and measurement tasks. The cross-segment connection is critical: cloud orchestration developed for high-volume X-ray or CT can lower deployment costs for specialized MRI, PET, and oncology applications. By 2030, platforms that combine modality breadth with indication-specific clinical evidence will hold the strongest position.
AI in Medical Imaging Market Regional Analysis
North America
North America held 43.8% market share in 2025. The United States anchors regional demand through FDA clearance activity, hospital IT spending, mature imaging infrastructure, and reimbursement pathways for selected AI applications. The FDA cleared 295 AI/ML-enabled devices in 2025, with radiology capturing 75% of authorizations. The American College of Radiology Data Science Institute's validation frameworks support more consistent vendor assessment by health systems.
Canada contributes through national digital-health adoption efforts and an integrated health system environment. The regional constraint is procurement complexity: hospital buyers still require evidence of workflow fit, cybersecurity controls, local validation, and reimbursement relevance before moving beyond pilot projects.
Europe
Europe represented 26.7% share in 2025. Germany leads deployment through hospital IT modernization, digital health reimbursement frameworks, and imaging technology investment. France, the UK, Spain, Italy, and the Netherlands contribute through national health systems and centralized procurement models.
EU MDR 2017/745 and the EU AI Act impose overlapping compliance requirements for diagnostic AI, while MDCG 2025-6 provides guidance on the interaction between medical-device and AI obligations. [7]European Commission Health and Food Safety, "MDCG 2025-6 Guidance on Medical Devices Regulation and the AI Act," health.ec.europa.eu The UK's NHS Transformation Directorate and NICE digital-health standards support structured AI evaluation in NHS trusts. The European Society of Radiology has issued recommendations related to AI Act implementation in radiology. [9]European Society of Radiology, "Recommendations for AI Act Implementation in Radiology," myesr.org Europe's constraint is not demand but fragmented compliance and procurement pathways across jurisdictions.
Asia Pacific
Asia Pacific held 22.1% share in 2025 and will remain the fastest-growing regional market. China's domestic AI imaging sector, India's expanding diagnostic infrastructure, and technology-integrated clinical deployments in Japan and South Korea support adoption. China-based vendors Infervision and DeepWise have achieved hospital deployment under national digital health and telemedicine expansion programs.
India's Ayushman Bharat Digital Mission supports digital-health infrastructure, while Qure.ai deploys qXR for tuberculosis screening and chest disease detection across government and private networks. Qure.ai operates in more than 25 countries. Japan and South Korea benefit from Canon Medical Systems and Samsung Medison integration of AI guidance and automated measurement tools into modality platforms. The regional constraint is uneven reimbursement and infrastructure maturity across countries, which favors cloud and mobile-first deployment in lower-resource settings.
Latin America
Latin America represented 4.5% share in 2025. Brazil is the largest regional contributor, followed by Mexico and Argentina. Telemedicine and digital-health investment are expanding imaging access, particularly in Brazil, where remote interpretation and cloud delivery are well suited to fragmented imaging-center networks.
Cloud-based AI can lower the infrastructure barrier for diagnostic networks that lack on-premises high-performance computing. Breast and cervical cancer screening expansion creates a direct demand pathway for AI-assisted imaging. Regulatory systems led by ANVISA in Brazil and COFEPRIS in Mexico continue to develop, creating both entry opportunity and market-access complexity.
Middle East and Africa
Middle East and Africa accounted for 2.9% share in 2025. Saudi Arabia and the UAE are investing in healthcare AI through national digital transformation initiatives and smart hospital programs. GE HealthCare, Siemens Healthineers, and Philips Healthcare have a strong role in Gulf Cooperation Council hospital deployments.
Across Sub-Saharan Africa, AI demand centers on portable X-ray, handheld ultrasound, tuberculosis screening, obstetric imaging, and remote triage. World Health Assembly resolution WHA78.13 urges integration of AI and clinical decision support into radiology information systems to strengthen equitable access to diagnostic imaging. [8]World Health Organization, "WHA78.13: Strengthening Medical Imaging Capacity," who.int The regional constraint is basic imaging and connectivity infrastructure, making low-cost, cloud-enabled, and mobile-first systems more commercially relevant than enterprise-scale architectures in many markets.
GMI Analyst View
Regional divergence will persist through 2035 because each market follows a different adoption logic. North America will remain the commercial benchmark for regulatory clearances, enterprise contracts, and reimbursement development. Europe will reward vendors that can operationalize compliance across multiple jurisdictions. Asia Pacific will provide the fastest incremental growth, led by China and India's imaging infrastructure expansion and domestic platform development. Latin America and MEA will favor deployment models that extend diagnostic capacity without requiring major local computing investments.
Artificial Intelligence in Medical Imaging Market Share & Competitive Landscape
The market is moderately consolidated. GE HealthCare, Siemens Healthineers, Philips Healthcare, Aidoc, and Viz.ai collectively held approximately 65% share in 2025. GE HealthCare led with approximately 23% share, supported by its imaging hardware installed base, Edison platform, and AI portfolio across CT, MRI, X-ray, ultrasound, and nuclear medicine.
Siemens Healthineers competes through AI-Rad Companion, syngo.via, SOMATOM CT, MAGNETOM MRI, ACUSON ultrasound, and Varian radiation therapy capabilities. Its advantage lies in embedding AI across diagnostic and therapeutic workflows. Philips Healthcare emphasizes enterprise imaging informatics, its Radiology Operations Command Center model, IntelliSite Pathology Solution, cardiac imaging tools, liver MRI applications, and AI-guided ultrasound.
Aidoc and Viz.ai are leading AI-native platforms. Aidoc's AI operating system and ORB platform coordinate detection, prioritization, communication, and multi-vendor algorithm management. Viz.ai extends imaging detection into care coordination by routing critical findings to specialists through mobile communication workflows. RapidAI competes in acute-care imaging, especially stroke, pulmonary embolism, aortic imaging, multiple sclerosis monitoring, and neurodegenerative assessment.
Canon Medical Systems integrates AiCE deep learning reconstruction into Aquilion CT and Vantage MRI systems. Fujifilm Holdings uses its REiLI platform across chest radiography, CT findings detection, and digital pathology. Tempus Radiology links imaging analytics with molecular and genomic data for precision oncology. Lunit provides chest X-ray and pathology products, while Qure.ai focuses on chest X-ray, CT brain analysis, and teleradiology for resource-limited settings.
Annalise.ai differentiates through multi-finding chest X-ray analysis. Subtle Medical provides MRI and PET image-quality enhancement through SubtleMR and SubtlePET. Rad AI automates report impressions and prior-comparison workflows. Cleerly provides quantitative coronary CT angiography analysis for plaque, stenosis, and ischemic risk assessment.
Our H2 2025 primary survey of 190 hospital procurement officers and IT directors across 9 countries indicated that vendor integration capability with existing PACS and RIS infrastructure was cited as the decisive purchase factor by 74% of respondents, with algorithm performance ranking second at 68%, underscoring the strategic importance of integration depth as a competitive differentiator in enterprise procurement.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →